

# CHALLENGING APPROACHES TO B-CELL MALIGNANCIES NEW DATA AND CLINICAL EXPERIENCES

**Lindner Hotel Prague • Czech Republic • October 12 –13 • 2017**

**EDUCATIONAL MEETING** scientifically coordinated by the Czech Lymphoma Study Group and the Czech CLL Study Group

**INTERNATIONAL FACULTY:** Leading key opinion leaders from academia and clinical practice

**VENUE:** Meeting and accommodation Lindner Hotel Prague (<https://www.lindner.de/en/prague-hotel-prague-castle/welcome.html>)

## DAY 1 • October 12 • 2017

### NON-HODGKIN LYMPHOMA – NEW TRENDS IN THERAPY

14.00 – 15.00 Arrival, registration

#### SESSION 1

15.00 – 15.05 Welcome and introduction by chairman  
*M. Trneny, Czech Republic*

15.05 – 15.30 DLBCL and FL biology  
*G. Lenz, Germany*

15.30 – 15.50 FL – first line therapy  
*M. Ghielmini, Switzerland*

15.50 – 16.10 Relapsed refractory FL  
*D. Belada, Czech Republic*

16.10 – 16.30 DLBCL – current a future management  
*V. Pejsa, Croatia*

16.30 – 16.50 Panel discussion

16.50 – 17.05 Coffee break

#### SESSION 2

17.05 – 17.25 Targeting elderly patients  
*S. Luminari, Italy*

17.25 – 17.45 PI3k inhibitors – update  
*A. Janikova, Czech Republic*

17.45 – 18.05 BTK inhibitors – update  
*V. Prochazka, Czech Republic*

18.05 – 18.25 Monoclonal antibodies  
*W. Jurczak, Poland*

18.25 – 18.45 Targeting immune system  
*A. Vranovsky / L. Drgona, Slovakia*

18.45 – 19.00 Panel Discussion

19.00 Summary and adjourn  
*M. Trneny, Czech Republic*

19.30 Dinner

## DAY 2 • October 13 • 2017

### CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)

#### SESSION 1

09.00 – 9.10 Welcome and introduction by chairman  
*L. Smolej, Czech Republic*

09.10 – 9.30 Biology of CLL, critical signaling pathways  
*M. Mraz, Czech Republic*

09.30 – 9.50 Significance of complex karyotype in CLL  
*A. Cuneo, Italy*

09.50 – 10.10 Comorbidities and functional status of  
CLL patients  
*V. Goede, Germany*

10.10 – 10.40 Chemoimmunotherapy in CLL  
*L. Smolej, Czech Republic*

10.40 – 11.00 Coffee break

#### SESSION 2

11.00 – 11.25 Novel oral inhibitors in CLL  
*M. Doubek, Czech Republic*

11.25 – 11.45 Idelalisib in clinical practice – case reports  
*M. Spacek, Czech Republic*

11.45 – 12.10 Practical management of idelalisib AEs  
*R. Urbanova, Czech Republic*

12.10 – 12.30 Expert panel discussion, Q&A session All faculty

12.30 – 13.30 Lunch

#### SESSION 3

13.30 – 13.55 Allogeneic stem cell transplantation in CLL  
*P. Dreger, Germany*

13.55 – 14.15 Minimal residual disease in CLL  
*D. Lysak, Czech Republic*

14.15 – 14.35 Projects of European Research Initiative on CLL  
*S. Pospisilova, Czech Republic*

14.35 – 14.55 Expert panel discussion, Q&A session All faculty

14.55 – 15.10 Summary and adjourn  
*L. Smolej, Czech Republic*

15.10 Departure